Mp35-02 Impact of Positive Bladder Cancer Family History on the Prognosis of Patients With Non-Muscle Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II (MP35)1 May 2024MP35-02 IMPACT OF POSITIVE BLADDER CANCER FAMILY HISTORY ON THE PROGNOSIS OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUÉRIN Mohamad Abou Chakra, Igor Duquesne, Michael Peyromaure, Sarah L. Mott, Mohamad Moussa, Hugo Bailly, and Michael O'Donnell Mohamad Abou ChakraMohamad Abou Chakra , Igor DuquesneIgor Duquesne , Michael PeyromaureMichael Peyromaure , Sarah L. MottSarah L. Mott , Mohamad MoussaMohamad Moussa , Hugo BaillyHugo Bailly , and Michael O'DonnellMichael O'Donnell View All Author Informationhttps://doi.org/10.1097/01.JU.0001009372.61513.54.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Multiple factors could impact the prognosis of patients with non-muscle-invasive bladder cancer (NMIBC) treated with BCG therapy. There is evidence that patients with first-degree relatives (FDR) with bladder cancer (BC) have an increased risk of BC, but there is scarce literature that describes the influence of such a history on oncological outcomes in FDR. Thus, the genetic contribution may have an impact on the response to BCG. METHODS: The National Phase II BCG/IFN trial database from the US and pooled multi-institutional databases from France (FR) and Lebanon (LB) (2000–2021) were queried for NMIBC patients treated with BCG. Cox regression models were used to evaluate the effect of BC family history on recurrence-free survival (RFS) and progression-free survival (PFS) while adjusting for patient and pathologic characteristics. RESULTS: There were 867 patients in the US cohort and 1232 patients in the FR/LB cohort who met the inclusion criteria. The two cohorts were similar in age (mean 68 vs 67 years), male predominance (76% vs 69%), and tumor grades. The percentage of patients with a FDR with BC were comparable (7% vs 8%). Patients in the FR/LB cohort were more likely to have CIS tumors (41% vs 24%, p<0.01). RFS and PFS stratified by having a FDR with BC is displayed in Fig 1 and 2 for the US and FR/LB cohorts, respectively. Having a FDR with BC was not significantly associated with RFS or PFS in the US cohort. Conversely, it was significantly associated with a 2.10 times increased risk of recurrence (p<0.01) and a 3.01 times increased risk of progression (p<0.01) in the FR/LB cohort. CONCLUSIONS: A family history of BC could have an important impact on the response to BCG. The difference in results between the cohorts may be due to multiple factors, including different characterization and penetration of mutations in BC tumors between Asians, Europeans, and Americans. These findings support the hypothesis that carcinogenesis is a dynamic process resulting in a variable phenotype across geography. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e580 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mohamad Abou Chakra More articles by this author Igor Duquesne More articles by this author Michael Peyromaure More articles by this author Sarah L. Mott More articles by this author Mohamad Moussa More articles by this author Hugo Bailly More articles by this author Michael O'Donnell More articles by this author Expand All Advertisement PDF downloadLoading ...